Led by $635m acquisition of Capsule Technologies , the US medical devices industry saw a rise of 21.05% in overall cross border deal activity during Q1 2021, when compared with the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

A total of 46 cross border deals worth $1.84bn were announced in Q1 2021, compared with the last four-quarter average of 38.00 deals.

venture financing was the leading category in the quarter with 25 cross border deals which accounted for 54.4% of all deals.

In second place was M&A with 17 deals, followed by private equity with four transactions, respectively accounting for 37% and 8.7% of overall cross border deal activity in the US medical devices industry during the quarter.

In terms of value of cross border deals, M&A was the leading deal category in the US medical devices industry with total deals worth $977.63m, while venture financing and private equity deals totalled $626.67m and $239.67m, respectively.

US medical devices industry cross border deals in Q1 2021: Top deals

The top five medical devices industry cross border deals accounted for 61.2% of the overall value during Q1 2021.

The combined value of the top five medical devices cross border deals stood at $1.13bn, against the overall value of $1.84bn recorded for the quarter.

The top five medical devices industry cross border deals of Q1 2021 tracked by GlobalData were:

1) Koninklijke Philips’ $635m acquisition of Capsule Technologies

2) The $240m acquisition of Alydia Health by Organon

3) Altium Capital , Axiom Associates , Colle Capital Partners , GV Management Co, Huamin Investment Management and Nextrans ‘ $90m venture financing of Hyperfine Research

4) The $82m venture financing deal with Scipher Medicine by Alumni Ventures Group , aMoon Partners , Echo Health Ventures , Khosla Ventures and Northpond Ventures

5) Adage Capital Management , Ally Bridge Group , Asahi Kasei Medical , Bain Capital Life Sciences , BlackRock , CaaS Capital Management , D1 Capital Partners , Endeavour Vision , Longitude Capital Management Co, Quaker Partners Management, Sunley House Capital Management , T Rowe Price Associates and Xeraya Capital Sdn’s private equity with Rapid Micro Biosystems for $81m.